{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:02:35Z","timestamp":1793044955773,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The objective of this meta\u2010analysis was to determine whether maternal exposure to statins is associated with increased rates of major congenital malformations and other adverse pregnancy outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed\/Medline, Web of Science and Reprotox\u00ae databases were searched. Cohort and case control studies with prenatal exposure to statins were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Analysis of five cohort studies and one case\u2013control study showed no significant increase in rate of major congenital malformations when the exposed group was compared with the control ([OR 1.27; 95% CI 0.80\u20132.04], [aOR 1.05; 95% CI 0.84\u20131.31]). A significant increase in heart defect risk was detected in the statin\u2010exposed group when unadjusted ORs were combined (OR 2.47; 95% CI 1.36\u20134.49). Further analysis of the same outcome by using adjusted ORs showed no significant increase in heart defect risk in the statin\u2010exposed group compared with the controls (aOR 1.24; 95% CI 0.93\u20131.66). A significantly lower live birth rate (OR 0.60, 95% CI 0.49\u20130.75) and a higher spontaneous abortion rate (OR 1.36; 95% Cl 1.06\u20131.75) were detected in the statin\u2010exposed group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Gestational statin exposure was not associated with a significant increase in risk of major congenital malformations, heart defects and other adverse pregnancy outcomes, except spontaneous abortion and live birth rate, which may be associated with maternal comorbidity and other unadjusted risk factors. Further research focusing on particular statins is needed to draw more definitive conclusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bcp.15423","type":"journal-article","created":{"date-parts":[[2022,5,31]],"date-time":"2022-05-31T11:22:56Z","timestamp":1653996176000},"page":"3962-3976","source":"Crossref","is-referenced-by-count":36,"title":["Pregnancy outcomes following maternal exposure to statins: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"88","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0917-2186","authenticated-orcid":false,"given":"Baris","family":"Karadas","sequence":"first","affiliation":[{"name":"Training and Research Center Terafar \u2010 Izmir Katip Celebi University Teratology Information  Izmir Turkey"},{"name":"Department of Pharmacology Izmir Katip Celebi University School of Medicine  Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0009-3951","authenticated-orcid":false,"given":"Nusret","family":"Uysal","sequence":"additional","affiliation":[{"name":"Training and Research Center Terafar \u2010 Izmir Katip Celebi University Teratology Information  Izmir Turkey"},{"name":"Department of Pharmacology Izmir Katip Celebi University School of Medicine  Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7145-3400","authenticated-orcid":false,"given":"Hilal","family":"Erol","sequence":"additional","affiliation":[{"name":"Department of Pharmacology Izmir Ege University School of Medicine  Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4083-8660","authenticated-orcid":false,"given":"Selin","family":"Acar","sequence":"additional","affiliation":[{"name":"Training and Research Center Terafar \u2010 Izmir Katip Celebi University Teratology Information  Izmir Turkey"},{"name":"Department of Pharmacology Izmir Katip Celebi University School of Medicine  Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3620-1261","authenticated-orcid":false,"given":"Meltem","family":"Koc","sequence":"additional","affiliation":[{"name":"Department of Family Medicine Izmir Katip Celebi University School of Medicine  Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0069-6576","authenticated-orcid":false,"given":"Tijen","family":"Kaya\u2010Temiz","sequence":"additional","affiliation":[{"name":"Training and Research Center Terafar \u2010 Izmir Katip Celebi University Teratology Information  Izmir Turkey"},{"name":"Department of Pharmacology Izmir Katip Celebi University School of Medicine  Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9234-0875","authenticated-orcid":false,"given":"Gideon","family":"Koren","sequence":"additional","affiliation":[{"name":"Adelson School of Medicine Ariel University  Israel"},{"name":"Motherisk International Program Shamir Hospital  Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-7934","authenticated-orcid":false,"given":"Yusuf C.","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Izmir University of Economics  Izmir Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.pec.0000530052.69853.4a"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/GCO.0000000000000026"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059344"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.4103\/2230\u20108210.163106"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2174\/138161209787315684"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.05.038"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.30386"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/toxs.1997.2400"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.20005"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420280316"},{"key":"e_1_2_10_12_1","unstructured":"Reprotox.https:\/\/reprotox.org\/member. Accessed December 7 2019."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1035"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1995"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1586\/erc.11.196"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.4176"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2008.06.009"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471\u20100528.12066"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1701\u20102163(15)30565\u2010X"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2018.07.002"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"key":"e_1_2_10_22_1","unstructured":"WellsGA SheaB O'ConnellD PetersonJ WelchV LososPT M.The Newcastle\u2010Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta\u2010analyses.http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. Accessed December 7 2019."},{"key":"e_1_2_10_23_1","unstructured":"EUROCAT.EUROCAT Guide 1.4 and Reference Documents.https:\/\/eu-rd-platform.jrc.ec.europa.eu\/sites\/default\/files\/Full_Guide_1_4_version_28_DEC2018.pdf. Published 2013. Updated December 28 2018. Accessed June 3 2022."},{"key":"e_1_2_10_24_1","unstructured":"HigginsJPT ThomasJ ChandlerJ CumpstonM LiT PageMJ WV eds.Cochrane Handbook for Systematic Reviews of Interventions version 6.2.www.training.cochrane.org\/handbook"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.327.7414.557"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.333.7568.597"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15542"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102125.2007.02905.x"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2015.12.038"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.990929"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/14767058.2015.1022864"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.5603\/GP.a2017.0084"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.114.03115"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0890\u20106238(96)00130\u2010x"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.32493"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.20181"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2003.11.003"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/pch\/14.7.450"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2004.02.014"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.30685"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38856.692986.AE"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2008.09.1920"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2021.05.006"},{"key":"e_1_2_10_44_1","first-page":"18","article-title":"EMEA\/CHMP\/203927\/2005 \u2010 Guideline on risk assessment of medicinal products on human reproduction and lactation: from data to labelling","author":"EMA","year":"2008","journal-title":"Eur Med Agency"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.c221"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15423","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.15423","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.15423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T07:54:20Z","timestamp":1692604460000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.15423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1111\/bcp.15423"],"URL":"https:\/\/doi.org\/10.1111\/bcp.15423","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}